CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The REAP project aims to develop advanced imaging systems to detect drug tolerant persister cells in cancer. It focuses on creating multimodal imaging technologies and novel contrast agents to enhance sensitivity and specificity in visualizing tumors, ultimately improving cancer treatment outcomes.
Cancer treatment faces a major problem: it ultimately stops working for many patients because the tumor becomes resistant.
The cellular origin of relapse is often linked to drug tolerant persister (DTP) cells, which survive treatment and can remain for years.
Because of their scarcity and heterogeneity, the detection of DTP cells remains a technological challenge of enormous clinical importance.
The objective of REAP is to develop two next generation multimodal imaging systems to reveal DTPs. A…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
UNIVERSIDADE DE SANTIAGO DE COMPOSTELA
Spain, Santiago De Compostela
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Finland, TAMPERE
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Finland, Tampere
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
